Cancer in experimental animals exposed to arsenic and arsenic compounds.
Inorganic arsenic is a ubiquitous environmental contaminant that has long been considered a human carcinogen. Recent studies raise further concern about the metalloid as a major, naturally occurring carcinogen in the environment. However, during this same period it has proven difficult to provide experimental evidence of the carcinogenicity of inorganic arsenic in laboratory animals and, until recently, there was considered to be a lack of clear evidence for carcinogenicity of any arsenical in animals. More recent work with arsenical methylation metabolites and early life exposures to inorganic arsenic has now provided evidence of carcinogenicity in rodents. Given that tens of millions of people worldwide are exposed to potentially unhealthy levels of environmental arsenic, in vivo rodent models of arsenic carcinogenesis are a clear necessity for resolving critical issues, such as mechanisms of action, target tissue specificity, and sensitive subpopulations, and in developing strategies to reduce cancers in exposed human populations. This work reviews the available rodent studies considered relevant to carcinogenic assessment of arsenicals, taking advantage of the most recent review by the International Agency for Research on Cancer (IARC) that has not yet appeared as a full monograph but has been summarized (IARC, 2009 , IARC Special Report: Policy, Vol. 10. Lyon: IARC Press, 453–454). Many valid studies show that arsenic can interact with other carcinogens/agents to enhance oncogenesis, and help elucidate mechanisms, and these too are summarized in this review. Finally, this body of rodent work is discussed in light of its impact on mechanisms and in the context of the persistent argument that arsenic is not carcinogenic in animals.
Tokar
Erik J
EJ
National Toxicology Program, National Institute of Environmental Health Sciences, and Laboratory of Comparative Carcinogenesis, National Cancer Institute at the National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA.
Benbrahim-Tallaa
Lamia
L
Ward
Jerrold M
JM
Lunn
Ruth
R
Sams
Reeder L
RL
Waalkes
Michael P
MP
D000818:Animals; D001151:Arsenic / Q000633:toxicity*; D001152:Arsenicals / Q000009:adverse effects*; D002273:Carcinogens / Q000633:toxicity*; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D008297:Male; D008745:Methylation; D051379:Mice; D008815:Mice, Inbred Strains; D009369:Neoplasms / Q000139:chemically induced*; D051381:Rats; D011919:Rats, Inbred Strains
D001152:Arsenicals; D002273:Carcinogens; D001151:Arsenic
IARC Monogr Eval Carcinog Risks Hum. 2004;84:1-477
15645577
Cancer Sci. 2007 Jun;98(6):803-14
17441966
Cancer Lett. 1998 Mar 13;125(1-2):83-8
9566700
Proc West Pharmacol Soc. 1983;26:413-5
6688469
Environ Res. 1984 Aug;34(2):227-41
6086305
Environ Health Perspect. 2010 Jan;118(1):108-15
20056578
Cancer Lett. 1985 May;27(1):99-104
4005826
Am J Pathol. 1998 Dec;153(6):1775-85
9846968
Toxicol Appl Pharmacol. 2005 Aug 22;207(1):69-77
16054901
Toxicol Appl Pharmacol. 2000 Jul 1;166(1):24-35
10873715
IARC Monogr Eval Carcinog Risks Hum. 2006;87:1-471
17191367
Environ Health Perspect. 2006 Aug;114(8):1293-6
16882542
Toxicol Appl Pharmacol. 2007 Aug 1;222(3):271-80
17306315
Cancer Lett. 2005 Jun 1;223(1):27-35
15890234
Verh Dtsch Ges Pathol. 1971;55:289-93
4130723
Int J Cancer. 1979 Dec 15;24(6):786-8
544532
Natl Toxicol Program Tech Rep Ser. 2000 Sep;492:1-306
12563348
Ann N Y Acad Sci. 2006 Sep;1076:578-91
17119234
Environ Health Perspect. 2004 Apr;112(5):599-603
15064167
Toxicol Appl Pharmacol. 2006 Sep 15;215(3):295-305
16712894
Toxicol Lett. 2005 Aug 14;158(2):87-94
16039397
Toxicology. 2006 Jun 1;223(1-2):82-100
16677751
Lab Invest. 2006 Dec;86(12):1203-7
17075578
Mutat Res. 1997 Jun;386(3):209-18
9219559
IARC Monogr Eval Carcinog Risk Chem Hum. 1980;23:1-415
6933135
Biol Pharm Bull. 2001 May;24(5):510-4
11379771
Carcinogenesis. 1996 Nov;17(11):2435-9
8968060
Toxicology. 2003 Aug 28;190(3):197-219
12927375
Environ Health Perspect. 2000 Jun;108 Suppl 3:573-94
10852857
Toxicol Appl Pharmacol. 2007 Dec 1;225(2):206-13
17765279
Endocr Pathol. 2008 Spring;19(1):9-16
18317952
Toxicol Appl Pharmacol. 2003 Jan 1;186(1):7-17
12583988
Vopr Onkol. 1986;32(3):68-73
3962260
Carcinogenesis. 2003 Nov;24(11):1827-35
12919961
Int J Cancer. 1987 Aug 15;40(2):220-3
3610389
Cancer Lett. 2000 Apr 28;152(1):79-85
10754209
J Pharmacokinet Pharmacodyn. 2008 Feb;35(1):31-68
17943421
Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1982-7
18708388
Carcinogenesis. 2004 Jan;25(1):133-41
14514661
Carcinogenesis. 2003 Feb;24(2):335-42
12584185
Carcinogenesis. 1996 Apr;17(4):767-70
8625489
Curr Opin Biotechnol. 2007 Oct;18(5):460-6
18023337
Cancer Lett. 1983 Dec;21(2):141-7
6652618
Carcinogenesis. 2005 Dec;26(12):2179-86
16014701
Toxicol Appl Pharmacol. 2001 Oct 1;176(1):64-71
11578149
Toxicol Appl Pharmacol. 2007 Aug 1;222(3):258-63
17109909
Cancer Res. 2008 Oct 15;68(20):8278-85
18922899
J Expo Sci Environ Epidemiol. 2009 May;19(4):343-8
19190673
Carcinogenesis. 2002 Aug;23(8):1387-97
12151359
Lancet Oncol. 2009 May;10(5):453-4
19418618
Toxicol Sci. 2006 Jun;91(2):372-81
16543296
Crit Rev Toxicol. 2009;39(8):695-718
19743946
Toxicol Appl Pharmacol. 2007 May 15;221(1):119-28
17400267
Jpn J Cancer Res. 2000 Jun;91(6):579-81
10874208
Mutat Res. 1997 Jun;386(3):181-4
9219556
Cancer Res. 2006 Feb 1;66(3):1337-45
16452187
Cancer Lett. 1998 Dec 11;134(1):29-36
10381127
Toxicol Lett. 2000 Jul 27;116(1-2):27-35
10906419
Carcinogenesis. 1999 Sep;20(9):1873-6
10469637
Toxicol Appl Pharmacol. 2008 Nov 1;232(3):359-68
18687352
Cancer Res. 1995 Mar 15;55(6):1271-6
7882321
IARC Monogr Eval Carcinog Risks Hum Suppl. 1987;7:1-440
3482203